Efficacy and retention rate of adalimumab in rheumatoid arthritis and psoriatic arthritis patients after first-line etanercept failure: the FEARLESS cohort
- 185 Downloads
Few studies have compared the efficacy of switching from etanercept to adalimumab in the real-life setting in rheumatoid arthritis (RA) and psoriatic arthritis (PsA). This study evaluated the 2-year retention rate and 12-month efficacy of adalimumab in RA and PsA patients, previously treated with etanercept. RA and PsA patients from 11 Italian Rheumatology Units received adalimumab after first-line etanercept failure. Two-year adalimumab retention rate was calculated by the Kaplan–Meier method and Cox proportional hazard models were developed to examine predictors of drug persistence. Univariate and multivariate logistic regression analyses were developed to examine potential predictors of 12-month DAS-28 remission. The study population included 117 RA (disease duration of 10.1 ± 7.7 years and baseline DAS28-ESR of 4.97 ± 1.3) and 102 PsA (disease duration of 7.1 ± 5.1 years and baseline DAPSA of 24.6 ± 11.8). The 2-year retention rate was 48.2% in RA and 56.5% in PsA patients. Concomitant methotrexate treatment was not associated with increased drug survival in both groups. Similarly, cause of etanercept discontinuation or treatment duration was not associated with retention rate. 12-month remission and low disease activity were achieved, respectively, in 27.3% and 23.9% of RA patients and 27.4% and 23.5% PsA of patients. In multivariate models, etanercept discontinuation due to inefficacy (OR 0.27, 95% CI 1.03–0.73; p = 0.009) and baseline DAS-28 (OR 0.45, 95% CI 0.29–0.69; p < 0.001) remained significant negative predictors of remission in RA patients. No variable was associated with remission in PsA patients. Adalimumab after etanercept failure was highly effective and safe in both RA and PsA patients.
KeywordsPsoriatic arthritis Rheumatoid arthritis Biological drugs Adalimumab Etanercept
Study concept and design: EGF, AB; data acquisition; EGF, AB, AC, FC, GA, EF, LQ, CGE, ALM, MB, FS, AS, SP, FC, IP, RF; analysis: EGF, AB, CGE; writing: EGF, CGE; interpretation of results; EGF, AB. All authors were involved in drafting the article or revising it critically for important intellectual content. All authors approved the final version to be submitted for publication.
Compliance with ethical standards
Ethics committee approval on 15/05/2008 from Gaetano Pini Institute, Milan, Italy (protocol no. 63/08) and written informed consent for the anonymous use of personal data were obtained from every patient, in compliance with Legislative Decree 196/2003. This study complies with the ethical standards laid down in the 1975 Declaration of Helsinki.
Conflict of interest
EGF served as a consultant and/or speaker for BMS, Lilly, Celgene, MSD, UCB, Pfizer, Sanofi-Genzyme, Novartis, and AbbVie. AB served as a speaker for Sanofi-Genzyme, UCB, and AbbVie. AC served as a consultant and/or speaker for BMS, Lilly, Celgene, MSD, Janssen, Roche, Sanofi, Sandoz and Novartis. FaC served as a consultant and/or speaker for BMS, Lilly, Celgene, Pfizer, and AbbVie. LQ served as a consultant and/or speaker for Celgene, Roche, Lilly, AbbVie, and Pfizer. ALM served as a consultant for Sanofi and Roche. MB served as a consultant and/or speaker for BMS, Lilly, Roche, Novartis, Janssen. FS served as a consultant and/or speaker for BMS, MSD, Pfizer, Novartis, and AbbVie. AS served as speaker for BMS, AbbVie, MSD, UCB, Novartis, Sanofi. SP served as consultant and/or speaker for AbbVie, Biogen, BMS, Celgene, Janssen, Lilly, Novartis and UCB. RF served as a consultant and/or speaker for BMS, Lilly, Celgene, MSD, UCB, Pfizer, Janssen, Novartis, and AbbVie. EF, FuC, CGE and IP declared no conflict of interest.
- 17.Becciolini A, Raimondo MG, Crotti C et al (2017) A review of the literature analyzing benefits and concerns of infliximab biosimilar CT-P13 for the treatment of rheumatologic diseases: focus on interchangeability. Drug Des Dev Ther 11:1969–1978. https://doi.org/10.2147/DDDT.S138515 CrossRefGoogle Scholar
- 18.Smolen JS, Kay J, Doyle MK et al (2009) Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet Lond Engl 374:210–221. https://doi.org/10.1016/S0140-6736(09)60506-7 CrossRefGoogle Scholar
- 19.Weinblatt ME, Fleischmann R, Huizinga TWJ et al (2012) Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study. Rheumatol Oxf Engl 51:2204–2214. https://doi.org/10.1093/rheumatology/kes150 CrossRefGoogle Scholar
- 20.Furst DE, Gaylis N, Bray V et al (2007) Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite study. Ann Rheum Dis 66:893–899. https://doi.org/10.1136/ard.2006.068304 CrossRefPubMedPubMedCentralGoogle Scholar
- 22.Glintborg B, Ostergaard M, Krogh NS et al (2013) Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor α inhibitor therapy: results from the Danish Nationwide DANBIO Registry. Arthritis Rheum 65:1213–1223. https://doi.org/10.1002/art.37876 CrossRefPubMedGoogle Scholar
- 23.Favalli EG, Sinigaglia L, Becciolini A et al (2018) Two-year persistence of golimumab as second-line biologic agent in rheumatoid arthritis as compared to other subcutaneous tumor necrosis factor inhibitors: real-life data from the LORHEN registry. Int J Rheum Dis 21:422–430. https://doi.org/10.1111/1756-185X.13199 CrossRefPubMedGoogle Scholar
- 25.Conti F, Ceccarelli F, Marocchi E et al (2007) Switching tumour necrosis factor alpha antagonists in patients with ankylosing spondylitis and psoriatic arthritis: an observational study over a 5-year period. Ann Rheum Dis 66:1393–1397. https://doi.org/10.1136/ard.2007.073569 CrossRefPubMedPubMedCentralGoogle Scholar
- 28.Lequerré T, Farran É, Ménard J-F et al (2015) Switching from an anti-TNF monoclonal antibody to soluble TNF-receptor yields better results than vice versa: an observational retrospective study of 72 rheumatoid arthritis switchers. Jt Bone Spine 82:330–337. https://doi.org/10.1016/j.jbspin.2015.01.021 CrossRefGoogle Scholar
- 30.Smolen JS, Burmester G-R, Combe B et al (2016) Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study. Lancet Lond Engl 388:2763–2774. https://doi.org/10.1016/S0140-6736(16)31651-8 CrossRefGoogle Scholar
- 31.Mease PJ, Fleischmann R, Deodhar AA et al (2014) Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a phase 3 double-blind randomised placebo-controlled study (RAPID-PsA). Ann Rheum Dis 73:48–55. https://doi.org/10.1136/annrheumdis-2013-203696 CrossRefPubMedGoogle Scholar
- 32.Greenberg JD, Reed G, Decktor D et al (2012) A comparative effectiveness study of adalimumab, etanercept and infliximab in biologically naive and switched rheumatoid arthritis patients: results from the US CORRONA registry. Ann Rheum Dis 71:1134–1142. https://doi.org/10.1136/annrheumdis-2011-150573 CrossRefPubMedGoogle Scholar
- 33.Virkki LM, Valleala H, Takakubo Y et al (2011) Outcomes of switching anti-TNF drugs in rheumatoid arthritis—a study based on observational data from the Finnish Register of Biological Treatment (ROB-FIN). Clin Rheumatol 30:1447–1454. https://doi.org/10.1007/s10067-011-1779-1 CrossRefPubMedGoogle Scholar
- 35.Rémy A, Avouac J, Gossec L, Combe B (2011) Clinical relevance of switching to a second tumour necrosis factor-alpha inhibitor after discontinuation of a first tumour necrosis factor-alpha inhibitor in rheumatoid arthritis: a systematic literature review and meta-analysis. Clin Exp Rheumatol 29:96–103PubMedGoogle Scholar
- 37.Gottenberg J-E, Brocq O, Perdriger A et al (2016) Non-TNF-targeted biologic vs a second anti-TNF drug to treat rheumatoid arthritis in patients with insufficient response to a first anti-TNF drug: a randomized clinical trial. JAMA 316:1172–1180. https://doi.org/10.1001/jama.2016.13512 CrossRefPubMedGoogle Scholar
- 38.Kaymakcalan Z, Sakorafas P, Bose S et al (2009) Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor. Clin Immunol Orlando Fla 131:308–316. https://doi.org/10.1016/j.clim.2009.01.002 CrossRefGoogle Scholar
- 39.Mitoma H, Horiuchi T, Tsukamoto H et al (2008) Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab. Arthritis Rheum 58:1248–1257. https://doi.org/10.1002/art.23447 CrossRefPubMedGoogle Scholar
- 40.Hyrich KL, Lunt M, Watson KD et al (2007) Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum 56:13–20. https://doi.org/10.1002/art.22331 CrossRefPubMedGoogle Scholar
- 43.Favalli EG, Becciolini A, Biggioggero M et al (2018) The role of concomitant methotrexate dosage and maintenance over time in the therapy of rheumatoid arthritis patients treated with adalimumab or etanercept: retrospective analysis of a local registry. Drug Des Dev Ther 12:1421–1429. https://doi.org/10.2147/DDDT.S162286 CrossRefGoogle Scholar
- 44.Soliman MM, Ashcroft DM, Watson KD et al (2011) Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 70:583–589. https://doi.org/10.1136/ard.2010.139774 CrossRefPubMedPubMedCentralGoogle Scholar
- 45.Fagerli KM, Lie E, van der Heijde D et al (2014) The role of methotrexate co-medication in TNF-inhibitor treatment in patients with psoriatic arthritis: results from 440 patients included in the NOR-DMARD study. Ann Rheum Dis 73:132–137. https://doi.org/10.1136/annrheumdis-2012-202347 CrossRefPubMedGoogle Scholar